☆ 4.2 Review

Use of convalescent plasma in COVID-19 patients with immunosuppression

TRANSFUSION (2021)

Related references

Note: Only part of the references are listed.

Review Infectious Diseases

Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency - Three consecutive cases and review of the literature

Marcial Delgado-Fernandez et al.

Summary: This article discusses the use of COVID-19 convalescent plasma (CCP) in patients with humoral immunodeficiency. The study suggests that CCP can improve clinical symptoms and shorten the duration of the disease for patients with congenital primary immunodeficiency or those on treatment with anti CD20 antibodies.

ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA (2022)

Add to Collection

Letter Public, Environmental & Occupational Health

Clinical illness with viable severe acute respiratory coronavirus virus 2 (SARS-CoV-2) virus presenting 72 days after infection in an immunocompromised patient

Carly M. Hughes et al.

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2022)

Add to Collection

Article Oncology

Successful Use of COVID-19 Convalescent Plasma in a Patient Recently Treated for Follicular Lymphoma

Zachary Wright et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2021)

Add to Collection

Article Immunology

Convalescent Plasma for Patients With Severe Coronavirus Disease 2019 (COVID-19): A Matched Cohort Study

Ralph Rogers et al.

Summary: The study did not find a significant difference in mortality risk or hospital discharge rate between patients treated with convalescent plasma and the control group. However, there was a signal for improved outcomes among elderly patients, and a higher frequency of transfusion reactions was observed in the convalescent plasma group. Further randomized studies focusing on the elderly subgroup are recommended.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Editorial Material Immunology

Emerging RNA-Dependent RNA Polymerase Mutation in a Remdesivir-Treated B-cell Immunodeficient Patient With Protracted Coronavirus Disease 2019

Martin Martinot et al.

Summary: A 76-year-old female with post-rituximab B-cell immuno-deficiency and persistent SARS-CoV-2 viremia developed a mutation in RdRP (D484Y) following treatment with remdesivir, but was successfully cured after supplementation with convalescent plasma.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Allergy

Coronavirus disease 2019 in patients with inborn errors of immunity: An international study

Isabelle Meyts et al.

Summary: The study shows that patients with IEI exhibit varied responses to SARS-CoV-2 infection, with some requiring hospitalization and even intensive care, and a non-negligible mortality rate. In comparison to the general population, younger IEI patients may face a higher risk of severe illness and mortality.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)

Add to Collection

Article Immunology

Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient

Ji Hoon Baang et al.

Summary: This case illustrates challenges in managing immunocompromised hosts with chronic COVID-19, who may act as persistent shedders and sources of transmission. The patient's lack of seroconversion and prolonged course highlight the importance of humoral immunity in resolving viral infections.

JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection

Article Hematology

Convalescent plasma to aid in recovery of COVID-19 pneumonia in a child with acute lymphoblastic leukemia

Ravi Shankar et al.

Summary: Most children with COVID-19 have mild infections, but those with cancer are considered a high-risk group for all infections. Currently, there are no established treatment guidelines for severe COVID-19 in children, with treatment often guided by adult recommendations lacking evidence-based support.

TRANSFUSION AND APHERESIS SCIENCE (2021)

Add to Collection

Article Hematology

Convalescent plasma therapy in patients with COVID-19

Fevzi Altuntas et al.

Summary: This study indicated that convalescent plasma (CP) therapy can reduce the duration in the intensive care unit, rates of mechanical ventilation support and vasopressor support in severe and critically ill patients with COVID-19, as well as decrease the case fatality rate. Early administration of CP after COVID-19 diagnosis is associated with a better outcome in terms of mechanical ventilation support.

TRANSFUSION AND APHERESIS SCIENCE (2021)

Add to Collection

Letter Hematology

Safety and efficacy of COVID-19 convalescent plasma in severe pulmonary disease: A report of 17 patients

Priya Pal et al.

TRANSFUSION MEDICINE (2021)

Add to Collection

Letter Hematology

Convalescent Plasma Rescued a Severe COVID-19 Patient with Chronic Myeloid Leukemia Blast Crisis and Myelofibrosis

Lu-Lu Zhang et al.

TURKISH JOURNAL OF HEMATOLOGY (2021)

Add to Collection

Letter Allergy

Clinical outcomes and features of COVID-19 in patients with primary immunodeficiencies in New York City

Hsi-en Ho et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)

Add to Collection

Article Pathology

Significantly Decreased Mortality in a Large Cohort of Coronavirus Disease 2019 (COVID-19) Patients Transfused Early with Convalescent Plasma Containing High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein IgG

Eric Salazar et al.

Summary: Convalescent plasma therapy containing high-titer anti-spike protein RBD IgG has shown to significantly reduce mortality in hospitalized COVID-19 patients when transfused within 44 hours, confirming previous findings and showing promise in the treatment of the disease.

AMERICAN JOURNAL OF PATHOLOGY (2021)

Add to Collection

Letter Hematology

Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies

Albrecht Betrains et al.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Add to Collection

Letter Immunology

Severe COVID-19 in Patients with B Cell Alymphocytosis and Response to Convalescent Plasma Therapy

Jonathan London et al.

JOURNAL OF CLINICAL IMMUNOLOGY (2021)

Add to Collection

Article Oncology

Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies

Silvia Ferrari et al.

Summary: This study described the use of hyperimmune plasma therapy in immunocompromised patients with hematological disorders during the SARS-CoV-2 outbreak, showing positive outcomes such as clinical improvement, recovery, and viral clearance. While further research is needed, the results suggest a specific role for hyperimmune plasma therapy in hematological patients.

LEUKEMIA & LYMPHOMA (2021)

Add to Collection

Article Medicine, General & Internal

Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults

R. Libster et al.

Summary: A randomized, double-blind, placebo-controlled trial of convalescent plasma with high IgG titers against SARS-CoV-2 in older adult patients within 72 hours after the onset of mild Covid-19 symptoms found that early administration of high-titer convalescent plasma reduced the progression of Covid-19 in mildly ill infected older adults.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19

M. J. Joyner et al.

Summary: This study found that higher anti-SARS-CoV-2 IgG antibody levels in convalescent plasma were associated with a lower risk of death among patients hospitalized with Covid-19 who were not receiving mechanical ventilation. The association between antibody levels and mortality risk was moderated by mechanical ventilation status, with no significant effect seen in patients who had already received ventilation.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

V. A. Simonovich et al.

Summary: There were no significant differences observed in clinical status or overall mortality between patients treated with convalescent plasma and those who received placebo in the treatment of severe Covid-19 pneumonia. The study results indicate that both groups had similar clinical outcomes and mortality rates after 30 days.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Immunology

COVID-19 in Solid Organ Transplant Recipients: Observations From Connecticut

Heather L. Kutzler et al.

TRANSPLANTATION (2021)

Add to Collection

Review Immunology

COVID-19 in solid organ transplant recipients: A systematic review and meta-analysis of current literature

Mohammed A. Raja et al.

Summary: A systematic review and meta-analysis of SOT recipients with SARS-CoV-2 infection revealed a high hospital admission rate and mortality rate. Common symptoms included fever and cough, with the majority of recipients requiring hospital treatment. Use of immunosuppressive medications decreased, while treatments varied.

TRANSPLANTATION REVIEWS (2021)

Add to Collection

Article Transplantation

Feasibility of Convalescent Plasma Therapy in Kidney Transplant Recipients With Severe COVID-19: A Single-Center Prospective Cohort Study

Akash Gupta et al.

Summary: The study demonstrates that convalescent plasma therapy is effective in improving clinical symptoms and laboratory markers in kidney transplant recipients with severe COVID-19, with a significant improvement within 7 days. The treatment is safe and feasible in this patient population and warrants further exploration through larger clinical registries and randomized clinical trials.

EXPERIMENTAL AND CLINICAL TRANSPLANTATION (2021)

Add to Collection

Article Infectious Diseases

Secondary hemophagocytic lymphohistiocytosis and severe liver injury induced by hepatic SARS-CoV-2 infection unmasking Wilson's disease: Balancing immunosuppression

Matthias Lubnow et al.

Summary: This case highlights the complexity of balancing immunosuppression to control hyperinflammation and prevent systemic SARS-CoV-2 dissemination during treatment.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection

Letter Immunology

A Patient with X-Linked Agammaglobulinemia and COVID-19 Infection Treated with Remdesivir and Convalescent Plasma

Aled Iaboni et al.

JOURNAL OF CLINICAL IMMUNOLOGY (2021)

Add to Collection

Letter Virology

Protracted SARS-CoV-2 pneumonia with rituximab treatment: About two cases

Victor Gerber et al.

JOURNAL OF MEDICAL VIROLOGY (2021)

Add to Collection

Article Virology

SARS-CoV-2-specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma

Monika Lindemann et al.

Summary: This case report presents the use of convalescent plasma (CP) in kidney transplant recipients and hemodialysis patients infected with SARS-CoV-2. Before treatment, low antibody levels were observed in the patients, but after CP treatment, there was a significant increase in specific antibodies and cellular responses. However, the success of CP therapy may be temporary, requiring close monitoring and potentially treatment adjustment in patients with chronic kidney disease.

JOURNAL OF MEDICAL VIROLOGY (2021)

Add to Collection

Letter Oncology

Severe clinical relapse in an immunocompromised host with persistent SARS-CoV-2 infection

Philipp A. Reuken et al.

LEUKEMIA (2021)

Add to Collection

Review Medicine, General & Internal

The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis

Stephen A. Klassen et al.

Summary: Studies show that COVID-19 convalescent plasma can lower mortality rates in patients, especially when administered early and with higher antibody titers.

MAYO CLINIC PROCEEDINGS (2021)

Add to Collection

Article Multidisciplinary Sciences

SARS-CoV-2 evolution during treatment of chronic infection

Steven A. Kemp et al.

Summary: Chronic infection with SARS-CoV-2 can lead to viral evolution and increased resistance to neutralizing antibodies in immunosuppressed individuals treated with convalescent plasma. During convalescent plasma therapy, there were significant shifts in the viral population structure and sensitivity, suggesting strong selection pressure on the virus during treatment.

NATURE (2021)

Add to Collection

Article Hematology

Two patients with rituximab associated low gammaglobulin levels and relapsed covid-19 infections treated with convalescent plasma

Irati Ormazabal Velez et al.

Summary: The use of convalescent plasma therapy in lymphoma patients with low gammaglobulin levels showed effectiveness in treating relapsed COVID-19, leading to clinical improvement and reducing the risk of virus relapse.

TRANSFUSION AND APHERESIS SCIENCE (2021)

Add to Collection

Article Hematology

Convalescent plasma therapy for severe Covid-19 in patients with hematological malignancies

Preethi Jeyaraman et al.

Summary: This retrospective multicentre study analyzed the 14-day mortality in 33 patients with hematological malignancies who received convalescent plasma therapy for severe Covid-19. The study found that patients who received plasma therapy early had a shorter duration of hospitalization. The overall mortality rate was 45.5%, with no significant impact of disease status, active therapy, or comorbidities on mortality.

TRANSFUSION AND APHERESIS SCIENCE (2021)

Add to Collection

Article Virology

Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19

Monika Maria Biernat et al.

Summary: The use of convalescent plasma in patients with hematological malignancies and COVID-19 can improve overall survival, reduce the severity of infection, and accelerate recovery.

VIRUSES-BASEL (2021)

Add to Collection

Article Allergy

Rapid clinical recovery of a SARS-CoV-2 infected common variable immunodeficiency patient following the infusion of COVID-19 convalescent plasma

Luciana C. Ribeiro et al.

Summary: This case report highlights the potential of using COVID-19 convalescent donor plasma as a valuable therapeutic approach for patients with common variable immunodeficiency and severe COVID-19. The patient showed rapid improvement after receiving four doses of convalescent plasma over a period of 6 days, with reduction of lung abnormalities and interruption of mechanical ventilation.

ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY (2021)

Add to Collection

Editorial Material Medicine, Research & Experimental

SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities

Arturo Casadevall et al.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Add to Collection

Article Medicine, General & Internal

Increased viral variants in children and young adults with impaired humoral immunity and persistent SARS-CoV-2 infection: A consecutive case series

Thao T. Truong et al.

Summary: The study highlights the concern that persistent infection of SARS-CoV-2 in immunocompromised hosts may lead to mutation accumulation and emergence of strains that evade immune responses. There is a need to reassess infection control precautions and consider routine surveillance of mutations for their potential impact on viral transmission and immune escape.

EBIOMEDICINE (2021)

Add to Collection

Article Immunology

Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products

Ariel Kenig et al.

Summary: This study demonstrates the therapeutic efficacy of convalescent plasma and plasma-based products in a subgroup of immunocompromised patients with iatrogenic B-cell depletion, showing significant clinical improvement and rapid viral clearance following plasma administration.

CLINICAL IMMUNOLOGY (2021)

Add to Collection

Article Immunology

Incidence and Outcomes of COVID-19 in Kidney and Liver Transplant Recipients With HIV: Report From the National HOPE in Action Consortium

Sapna A. Mehta et al.

Summary: Among kidney and liver transplant recipients with HIV, there was a 4% incidence rate of COVID-19 with high mortality. Most patients required hospitalization and aggressive treatment with high-dose steroids, tocilizumab, remdesivir, and convalescent plasma.

TRANSPLANTATION (2021)

Add to Collection

Article Hematology

SARS-CoV-2 convalescent plasma therapy in pediatric patient after hematopoietic stem cell transplantation

Dmitry Balashov et al.

Summary: A 9-month-old girl with juvenile myelomonocytic leukemia who received HSCT from a haploidentical donor developed bilateral viral pneumonia due to SARS-CoV-2 infection, which was partially resolved with tocilizumab and convalescent plasma therapy. However, complete elimination of the virus was not achieved after 4 months, likely due to persistent immunodeficiency and lack of adaptive immune response post-HSCT. This case highlights the potential effectiveness of convalescent plasma in combination with other therapies for treating COVID-19 in immunocompromised patients.

TRANSFUSION AND APHERESIS SCIENCE (2021)

Add to Collection

Article Infectious Diseases

COVID-19 Coinfection with Mycobacterium abscessus in a Patient with Multiple Myeloma

Jose A. Rodriguez et al.

Summary: This case report underscores the importance of maintaining a broad differential diagnosis and considering multiple coinfections, including atypical ones during the COVID-19 pandemic, such as the co-infection of SARS-CoV-2 and Mycobacterium abscessus discussed above, in order to provide goal-directed therapy.

CASE REPORTS IN INFECTIOUS DISEASES (2021)

Add to Collection

Article Cell Biology

Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency

Kazuhito Honjo et al.

Summary: Convalescent plasma (CP) has beneficial effects in severely ill COVID-19 patients, even when administered relatively late in the disease course. However, there are widely varying neutralizing antibody (NAbs) titers within different CP units, highlighting the importance of determining neutralizing activity for maximizing therapeutic benefits.

CELL REPORTS MEDICINE (2021)

Add to Collection

Article Cell & Tissue Engineering

Usefulness of Plasma SARS-CoV-2 RNA Quantification by Droplet-based Digital PCR to Monitor Treatment Against COVID-19 in a B-cell Lymphoma Patient

Tali-Anne Szwebel et al.

Summary: A HIV-1-infected patient with chronic COVID-19 was treated with anti-CD20 monoclonal antibody for B-cell lymphoma, but the treatment's viral efficacy was confirmed to be poor through monitoring plasma SARS-CoV-2 RNA by ddPCR. The patient's complete recovery after COVID-19 convalescent plasmatherapy was closely associated with clearance of plasma SARS-CoV-2 RNA.

STEM CELL REVIEWS AND REPORTS (2021)

Add to Collection

Article Pathology

Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma

Eric Salazar et al.

AMERICAN JOURNAL OF PATHOLOGY (2020)

Add to Collection

Editorial Material Medicine, Research & Experimental

The convalescent sera option for containing COVID-19

Arturo Casadevall et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

Add to Collection

Review Medicine, Research & Experimental

Deployment of convalescent plasma for the prevention and treatment of COVID-19

Evan M. Bloch et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

Add to Collection

Article Multidisciplinary Sciences

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Kai Duan et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)

Add to Collection

Article Immunology

Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease 2019

Qing-Lei Zeng et al.

JOURNAL OF INFECTIOUS DISEASES (2020)

Add to Collection

Article Virology

Treatment with convalescent plasma for COVID-19 patients in Wuhan, China

Mingxiang Ye et al.

JOURNAL OF MEDICAL VIROLOGY (2020)

Add to Collection

Article Hematology

Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis

Olgu Erkin Cinar et al.

TRANSFUSION AND APHERESIS SCIENCE (2020)

Add to Collection

Editorial Material Medicine, General & Internal

The Untold Toll - The Pandemic's Effects on Patients without Covid-19

Lisa Rosenbaum

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Letter Surgery

Convalescent plasma therapy: Helpful treatment of COVID-19 in a kidney transplant recipient presenting with serve clinical manifestation and complex complications

Jipin Jiang et al.

CLINICAL TRANSPLANTATION (2020)

Add to Collection

Article Hematology

Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion

Xinyi Xia et al.

BLOOD (2020)

Add to Collection

Article Hematology

Use of convalescent plasma in hospitalized patients with COVID-19: case series

Livia Hegerova et al.

BLOOD (2020)

Add to Collection

Letter Biophysics

COVID-19 in allogeneic stem cell transplant: high false-negative probability and role of CRISPR and convalescent plasma

Alex Niu et al.

BONE MARROW TRANSPLANTATION (2020)

Add to Collection

Letter Hematology

Convalescent plasma for persisting COVID-19 following therapeutic lymphocyte depletion: a report of rapid recovery

Evangeline Clark et al.

BRITISH JOURNAL OF HAEMATOLOGY (2020)

Add to Collection

Letter Allergy

Rapid recovery of a SARS-CoV-2-infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma

Estefania Mira et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2020)

Add to Collection

Article Oncology

A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward

Bo Wang et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

Add to Collection

Letter Oncology

Response to COVID-19 in persons with haematological cancers

Stefan Hatzl et al.

LEUKEMIA (2020)

Add to Collection

Article Hematology

Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19

Thomas Hueso et al.

BLOOD (2020)

Add to Collection

Article Medicine, General & Internal

Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

A. B. Cavalcanti et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Letter Urology & Nephrology

Outcomes of COVID-19 positive kidney transplant recipients: A single-center experience

Goni Katz-Greenberg et al.

CLINICAL NEPHROLOGY (2020)

Add to Collection

Article Surgery

Treatment with convalescent plasma in solid organ transplant recipients with COVID-19: Experience at large transplant center in New York City

Farah Rahman et al.

CLINICAL TRANSPLANTATION (2020)

Add to Collection

Article Hematology

Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study

Hassan Abolghasemi et al.

TRANSFUSION AND APHERESIS SCIENCE (2020)

Add to Collection

Article Hematology

Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma

Ayse Karatas et al.

TRANSFUSION AND APHERESIS SCIENCE (2020)

Add to Collection

Article Immunology

COVID-19 in recent heart transplant recipients: Clinicopathologic features and early outcomes

Brian Lima et al.

TRANSPLANT INFECTIOUS DISEASE (2020)

Add to Collection

Article Immunology

Early Experience With COVID-19 and Solid Organ Transplantation at a US High-volume Transplant Center

Stephanie G. Yi et al.

TRANSPLANTATION (2020)

Add to Collection

Letter Oncology

Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia

Guido Lancman et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

Add to Collection

Article Immunology

Coronavirus Disease 2019 Viremia, Serologies, and Clinical Course in a Case Series of Transplant Recipients

Johanna Christensen et al.

TRANSPLANTATION PROCEEDINGS (2020)

Add to Collection

Article Oncology

Convalescent Plasma for the Treatment of Severe COVID-19 Infection in Cancer Patients

Douglas Tremblay et al.

CANCER MEDICINE (2020)

Add to Collection

Letter Allergy

Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma

Haoli Jin et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2020)

Add to Collection

Article Hematology

COVID-19 convalescent plasma clears SARS-CoV-2 refractory to remdesivir in an infant with congenital heart disease

Zahidee Rodriguez et al.

BLOOD ADVANCES (2020)

Add to Collection

Article Hematology

Successful transfer of anti-SARS-CoV-2 immunity using convalescent plasma in an MM patient with hypogammaglobulinemia and COVID-19

Tim Luetkens et al.

BLOOD ADVANCES (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer

Victoria A. Avanzato et al.

CELL (2020)

Add to Collection

Letter Medicine, General & Internal

Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer

Teresa Aydillo et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Multidisciplinary Sciences

Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report

Matthew S. Buckland et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Article Infectious Diseases

Atypical course of COVID-19 in patient with Bruton agammaglobulinemia

Ivana Milosevic et al.

JOURNAL OF INFECTION IN DEVELOPING COUNTRIES (2020)

Add to Collection

Article Medicine, General & Internal

A 63-Year-Old Woman with a History of Non-Hodgkin Lymphoma with Persistent SARS-CoV-2 Infection Who Was Seronegative and Treated with Convalescent Plasma

Joanna L. Moore et al.

AMERICAN JOURNAL OF CASE REPORTS (2020)

Add to Collection

Article Infectious Diseases

Early use of tocilizumab in respiratory failure associated with acute COVID -19 pneumonia in recipients with solid organ transplantation

Suresh J. Antony et al.

IDCASES (2020)

Add to Collection

Article Gastroenterology & Hepatology

COVID-19 in Liver Transplant Recipients - A Series with Successful Recovery

Ashok Choudhury et al.

JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY (2020)

Add to Collection

Article Pediatrics

Humoral Immune Deficiencies of Childhood

Marwa El-Bohy et al.

PEDIATRIC CLINICS OF NORTH AMERICA (2019)

Add to Collection

Review Immunology

Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution

Keith A. Sacco et al.

IMMUNOTHERAPY (2018)

Add to Collection

Article Allergy

Common Variable Immunodeficiency Diagnosis, Management, and Treatment

Jordan K. Abbott et al.

IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA (2015)

Add to Collection

© Peeref 2019-2024. All rights reserved.